[Surgical therapy for hepatocellular carcinoma with liver cirrhosis].
Approximately 80% of hepatocellular carcinoma (HCC) patients in Japan have associated liver cirrhosis, which increases the difficulty of surgical treatment. Liver dysfunction associated with liver cirrhosis is one of the most important predictive prognostic factors for HCC patients. Percutaneous ethanol injection therapy (PEIT) is useful for patients with small HCC or with poor hepatic functional reserve. Transcatheter arterial chemoembolization (TACE) is also useful both for patients with unresectable HCC and patients with multiple intrahepatic recurrence. Liver resection, however, lead to better outcome than other treatments when liver function is maintained after surgery. To determine operative procedures, it is important to evaluate the exact function of remnant liver, based on the preoperative liver function test and the evaluation of tumor character. For advanced HCC patients with vascular invasion, non-surgical treatments such as PEIT or TACE are not indicated, and surgical intervention can be an effective modality to improve their survival. Improvements of surgical technique and perioperative management have decreased fatal complications at a major liver resection and allowed us to carry out liver resection on patients with advanced HCC.
Ikai
I
I
Department of Gastroenterological Surgery, Kyoto University Graduate School of Medicine, Japan.
Yamamoto
Y
Y
Ozaki
N
N
Sakai
Y
Y
Shimahara
Y
Y
Yamaoka
Y
Y
D006528:Carcinoma, Hepatocellular / Q000601:surgery* / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D000431:Ethanol / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D015552:Injections, Intralesional; D008103:Liver Cirrhosis / Q000150:complications*; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000601:surgery* / Q000628:therapy; D011183:Postoperative Complications
D000431:Ethanol